(Reuters) – Eli Lilly and Co said on Friday a U.S. District Court ruled in favor of its patent on Alimta vitamin regimen and prevented Hospira Inc and India’s Dr. Reddy’s Laboratories from launching generics until the patent expires.

FILE PHOTO: The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 18, 2018. REUTERS/Brendan McDermid

The patent for Lilly’s top-selling cancer drug will expire in May 2022.

“Lilly’s extensive research to discover the Alimta vitamin regimen patent deserves intellectual property protection,” Lilly’s senior vice president Michael Harrington said in a statement.

Lilly has faced several legal challenges to its right to avoid generic competition for Alimta, whose chemical name is pemetrexed.

Reporting by Vibhuti Sharma in Bengaluru; Editing by Arun Koyyur

Story originally published at Reuters.com

How the staff rate this post.
How do you rate this post?
[Total: 0 Average: 0]